Mylan Inc. (NYSE:MYL) recently announced that it has entered into a settlement agreement with Sunovion Pharmaceuticals Inc., a subsidiary of Japanese pharmaceutical company, Dainippon Sumitomo Pharma Co., Ltd.
The patent litigation was related to Sunovion’s Brovana, which is approved for controlling the symptoms of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
Sunovion recognized that Brovana infringed two of Mylan’s patents, which are valid till June … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards